Why is Thermo Fisher Scientific Inc. stock rising?
2026 organic growth outlook raised to about 4%, with second-half growth expected to step up to 4%.
SHL Medical collaboration will use the Ridgefield, New Jersey sterile fill-finish site to offer integrated sterile fill-finish and device assembly.
Reshoring contracts signed in CDMO; bioproduction revenue expected mainly in 2027-2028.
Filtration and separation business capacity is being increased to support future demand.
Get valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Thermo Fisher Scientific Inc. and 4,900+ companies.